Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
Samsung Medical Center
100,000 participants
Oct 22, 2024
OBSERVATIONAL
Conditions
Summary
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
Eligibility
Inclusion Criteria3
- Patients who underwent PCI
- Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
- No use of PCAB, PPI, or an H2-receptor within the past month
Exclusion Criteria2
- Patients with low GI bleeding risk are taken on PPI
- Patients with high GI bleeding risk do not take PPI
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This group received P-CAB with DAPT after PCI.
This group received PPI or not with DAPT after PCI according to GI bleeding risk.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07068490